A Comprehensive Report for decision making

Drug Developer's Intelligence Report

Oncology Intelligence

2014

This Report is only Available on request...

Kindly Check the Latest Updated Volume of this Report​

RELEASED - JANUARY 2014

931

Oncology Drug Developers

This report contains enough data to make strategic decisions especially for new entrants.

- Dr. Mitsuyoshi Nishizaki

Second Updated Edition - oncology intelligence 2014 Report

Report to Cover all Aspects of Cancer Drug Development Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

OI 2014 Vs OI 2013
(in terms of Oncology Drug Developers Number)

UPDATED DATA for
ACCURATE DECISIONS

 

OI 2014 is a key update over previous report OI 2013, as it may covers 398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period.

largest coverage

providing intelligence at fingertips

1
Countries

Largest Coverage with 33 Countries covered Globally

1
Drug developers

523 Clinical, 360 Preclinical & 48 Discovery Companies Profiles

1
Molecules

Individual Drug Mechanism of Action & Drug Target

1
Cancer Targets

Emerging Cancer Drug Targets Details

intelligence supercharged

1055 pages full of insights

Today Cancer Research comprises the largest set of drugs in development with equal increasing robust number of drug developers. Similarly with span of time due to numerous factors, abandoned rate of drugs / developers are also increasing, thus altogether making it time taking process to identify actionable intelligence in this highly technology driven domain.  

 

Oncology Drug Report 2014 –World’s Largest Active Resource for Decision Making, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.

 

Report for the first time identifies and profiles 931 Active Cancer Drug Development companies from 33 countries worldwide, developing 2237 cancer-targeting drugs. It evaluates 19 major cancer indications drug development pipeline and analysis it to provide thousands of active clinical trials information; cancer drug targets, molecule types etc., thus all together to bring the most updated and robust information at the fingertips. It creates immense authentic knowledgebase (all information with references) on thousands of Proprietary technologies, M&A deals and partnering occurring in cancer domain in last 10 years.  

 

A Single Innovative and Unique Report provide Answers to Many: –

 

  1. Covers 523 clinical, 408 Preclinical and Discovery stage companies along with their current partners, technologies and cancer drug pipeline, thus providing immense opportunities in identifying emerging cancer companies.
  2. Provides LinkedIn/E-mail IDs of all decision makers in individual clinical companies. These thousand’s of focused links helps in saving time in linking to right person, to further work on finer details.
  3. 19 Major Cancer Indications Individual Drug Development Pipeline and its Analysis, Market Size and Forecast and all possible new launces in next 3-5 years.
  4. 18 other Cancers Indications drug development pipeline, with the special sections to orphan status and rare cancer indications.
  5. For researcher, it covers 228 Emerging Cancer Drug Targets including 60+ Protein kinases, 2200+ drugs mechanism of action, their first and best in class status. This robust drug target data greatly aids in identifying and predicting emerging personalized cancer drug discovery programs.
  6. First time demarks Top 10 Cancer Drug Developers drug development strategies with reference to cancer drug targets, cancer indications and their emerging partnering preferences.
  7. All finer details are elaborated in the individual 931 companies profiles, all written in form of mini reports.
  8. Offers complete and focused lead identification details for Bio suppliers /CROs.
  9. Complete 1055 Pages report is interlinked with 10,000+ links and all Clinical Trials are hyperlinked to reach external validating links.
  10. The Text is supplemented with 139 Tables and 73 Figures/Info graphics.

 

 

Oncology Drug Report 2014, is the second updated edition, and its preceding last year release – Oncology Intelligence 2013, covered 624 companies, with 1600+ molecules in development, and was a highly successful report. This new edition covers some 378 more companies and eliminates 65 companies, which were either acquired/merged or had abandoned their oncology drug development program.

Table of Content:-

List of Figures

List of Tables

List of Boxes

List of Clinical Companies

List of Pre-clinical Companies

List of Discovery Companies

Executive Summary.

Section A : Oncology Companies with Active Drug Development Pipeline – Infographics

Worldwide Distribution of Companies with A ctive Cancer Drug Pipeline

Quantitative Estimation of Cancer Drug Developers present in U.S.A vs. Europe vs. Asia vs. Canada vs. Australia vs. Rest of the World (931 Companies)

Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in U.S.A (468 companies)

Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Europe (270 companies)

Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Asia (132 companies)

Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in Europe and Asia Region.

To identify best and emerging countries, for promoting cancer drug development in the region.

State-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in U.S.A.

To explore the Top cancer innovation supporting States in United States.

Distribution of 931 companies, on the basis of year of Establishment

To explore the emergence of Cancer Drug Discovery And Development.

Quantitative Estimation of Oncology Drug Developers on the basis of Human Resource Employed.

Top 10 cancer drug development companies (in terms of employee numbers), with their total employees vs. total number of R&D staff for past three consecutive years.

Section B : Active Oncology Drugs and Targets in Development – Key Intelligence

Distribution of Oncology Molecules in Clinical Development (2237 molecules)

Total number of Small, Biologics and Non Biological complex molecules in clinical development.

Total number of cancer molecules in development in USA, Europe, Asia and Rest of the World.

Molecule development strategies – Top 10 companies vs. remaining 921 companies.

Top 20 Oncology Drug Development Companies (In terms of molecules in Clinical Development)

Top 20 Cancer clinical development companies, their molecule types (small, biologics & NBCM),

clinical phases and total Indications of development.

Monoclonal Antibodies in Clinical Development (173 molecules)

Monoclonal antibodies in clinical development with developer and partner name, antibody target, isotype and drug development indications.

Monoclonal Antibodies in Pre-Clinical Development (193 molecules)

Monoclonal antibodies in preclinical & discovery development with developer name, antibody target and drug development indications.

Cancer Vaccines in Clinical Development (134 molecules)

Cancer Vaccines in clinical development with short description, developer and partner name, drug target and development Indications.

Cancer Vaccines in Pre-Clinical Development (50 molecules)

Cancer Vaccines in Pre-clinical & Discovery development with developer name, drug target and devel­opment Indications.

Cancer Targeting Antibodies Drug Conjugates in Clinical Development (42 molecules)

ADCs in clinical development, with short description of antibody and toxin attached; developer and partner name; its target and development Indications.

Cancer Targeting Radio-Immuno Conjugates in Clinical Development (10 molecules)

Radio-Immuo Conjugates in clinical development, with short description of antibody and radio isotope attached; developer and partner name; its target and development Indications.

Cancer Targeting Recombinant/Fusion Protein Therapies in Development (49 molecules)

Recombinant/Fusion Protein in clinical development with short description, developer and partner name, their targets and development Indications.

Cancer Targeting Synthetic Peptides in Clinical Development (19 molecules)

Synthetic peptides/proteins in clinical development with short description, developer and partner name, their targets and development Indications.

Oncolytic Virus Based/Gene Therapies in Clinical Development (33 molecules)

Oncolytic virus based Therapies in clinical development with short description, its developer and partner name; drug target and development Indications.

Cell Based Therapies for cancer treatment in Clinical Development (19 molecules)

T-Cell, Stem Cell and Other Cell based therapies in clinical development with short description, its developer and partner name; drug target and development Indications.

Other Biological Therapies in Clinical Development (23 molecules)

Remaining biological therapies in clinical development for cancer treatment, with short description, their developer and partner name; drug target and development Indications.

Protein Kinases – An Emerging Class of Cancer Drug Targets

Protein kinases vs other cancer drug targets in clinical development;

Comparative developmental profile of protein kinases, with their molecules and indications numbers.

Top four kinases classes targeting cancer with their molecule numbers;

Cancer targeting kinases development strategies – Top 10 companies vs. Remaining 921 companies.

Established kinases in cancer drug discovery, their FDA approval years; Annual sales and indications.

Anticipated protein kinases launch In 2014-15, with cancer indications.

Complete List of Emerging Cancer Drug Targets (228 Targets)

Protein Kinases as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target.  (55 Major Protein Target Classes)

Tumor Necrosis Factors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular

Location & Functions, Short Description with drugs in clinical development for the target.  (11 Major Protein Targets)

G-coupled Receptors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. (9 Major Protein Targets)

Tumor Surface Antigens as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. (22 Major Protein Targets)

Transcription Factors as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular

Location & Functions, Short Description with drugs in clinical development for the target. (14 Major Protein Targets)

Targeting Cellular Metabolites as Cancer Drug Targets –Target Name, Gene, Protein Family,

Cellular Location & Functions, Short Description with drugs in clinical development for the target. (14 Major Protein Targets)

Growth Factor as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. (8 Major Protein Targets)

Miscellaneous Other Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. (95 Targets)

Section C : Oncology Indications in various Developmental Stages- Intelligence

Distribution of Oncology Indications in Clinical Development (4264 indications)

Division of 4264 indications for 2237 Molecules, in drugs types – Small, Biologic and NBCM.

Geographic distribution of Clinical Indications and its correlation with number of molecules from similar region in development; Phase-Wise Breakup of total Indications;

Cancer Clinical Indications strategies – Top 10 companies vs. remaining 513 companies;

Comparative analysis on the preference of Top 10 companies for Small Molecule Vs. Biologics, in compare to remaining 513 companies.

Drug Development Strategies- Top 10 Companies vs. Remaining 921 Companies

A competitive intelligence de-marking the preference of Large Pharma Majors to Small Innovators – their choice of targets; cancer indications and types of molecules development.

–Drug Development Profile & Pipeline Analysis – Lung Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:– NSCLC

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against NSCLC;

Top 10 companies vs. others strategies in Lung Cancer Drug Development.

Pipeline Analysis:– SCLC

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Drug Development Profile & Pipeline Analysis – Breast Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Breast cancer;

Top 10 companies vs. others strategies in Breast Cancer Drug Development.

 

Drug Development Profile & Pipeline Analysis – Colorectal Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Colorectal cancer;

Top 10 companies vs. others strategies in Colorectal Cancer Drug Development.

Drug Development Profile & Pipeline Analysis – Melanoma Cancer

An Overview to Disease, Epidemiology; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Melanoma cancer;

Top 10 companies vs. others strategies in Melanoma Cancer Drug Development.

Drug Development Pipeline:– Other Skin Cancers including Non-Melanoma Cancers.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Drug Development Profile & Pipeline Analysis – Prostate Cancer

An Overview to Disease, Epidemiology; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Prostate cancer;

Top 10 companies vs. others strategies in Prostate Cancer Drug Development.

Drug Development Profile & Pipeline Analysis – Ovarian Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Ovarian cancer;

Top 10 companies vs. others strategies in O varian Cancer Drug Development.

Drug Development Pipeline:– Gynaecologic Malignancies.

Cervical Cancer – Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

Fallopian Tube Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Peritoneal Cancer – Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

Endometrial Cancer – Detailed Ph III, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, part­ners and targets).

–Drug Development Profile & Pipeline Analysis – Pancreatic Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Pancreatic cancer;

Top 10 companies vs. others strategies in Pancreatic Cancer Drug Development.

Drug Development Pipeline:– Gastrointestinal Tract Cancers.

Oesophageal Cancer- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).

Biliary Tract Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Gallbladder Cancer – Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Cholangiocarcinoma -Detailed Ph III, Ph II, Ph I & preclinical Pipeline (including developers, partners & targets).

Anal Cancer – Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Gastrointestinal Stromal Tumor- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

Drug Development Profile & Pipeline Analysis – Hepatocellular Carcinoma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Drug Development Profile & Pipeline Analysis – Gastric Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Drug Development Profile & Pipeline Analysis – Multiple Myeloma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Drug Development Profile & Pipeline Analysis – Leukemia

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Pipeline Analysis:– Leukemia

Acute Myeloid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Acute Myelogenous Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Acute Lymphoid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Acute Lymphocytic Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Chronic Myeloid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Chronic Myelogenous Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Chronic Myelomonocytic Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

Chronic Lymphoid Leukemia – Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.

 

Drug Development Profile & Pipeline Analysis – Non-Hodgkin Lymphoma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Pipeline Analysis:– Waldenstrom’s Macroglobulinemia

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Drug Development Profile & Pipeline Analysis – Hodgkin Lymphoma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Drug Development Profile & Pipeline Analysis- Brain Cancer (including Glioblastoma)

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:Glioblastoma

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Neuroblastoma – Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).

Medulloblastoma – Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).

Anaplastic Astrocytoma- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).

 

Drug Development Profile & Pipeline Analysis- Head & Neck Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:Glioblastoma

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Nasopharynx Cancer– Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).

Oral Cancer- Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).

 

Drug Development Profile & Pipeline Analysis – Renal Cell Carcinoma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Wilm’s Tumor – Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).

 

Drug Development Profile & Pipeline Analysis – Bladder Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Drug Development Profile & Pipeline Analysis – Thyroid Cancer

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Drug Development Profile & Pipeline Analysis – Sarcoma

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling targeted therapies -their Annual Sales & Forecast;

Pipeline Analysis:

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

 

Other Rare Cancer Indications – Developmental Pipeline Detailed PhIII, Ph II, Ph I, Pre

clinical & Discovery Pipeline (including developers, partners, targets and indications).

 

Orphan Drug Status drugs in development for Cancer Treatment

Name of Drug and Developer, its Orphan drug Indications and Orphan status providing agencies –

US FDA and EMEA.

 

US FDA New Oncology Drug Approvals – 2013

Developer, Approval month, Partner, Drug’s Proprietary Name, Approved Indication.

 

Oncology Clinical Pipeline – Major Phase III Failures – 2013

Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).

 

Section D : Individual Oncology Company Profile (with Active Clinical Pipeline)

A to Z Alphabetical Profiles of Cancer Clinical Drug Developer Companies (523 Companies)

Individual company Pages includes: Company Profile – Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

Clinical Pipeline Profile– Drug name, its target description, various development indications for cancer cure with current clinical trials and trials status (Active, Recruiting, Completed etc), FDA/EMEA Orphan drug status, Special Protocol Assessment, fast track approvals etc; company’s pre-clinical & discovery pipeline.

Management Profile –Address, Contact phone number, e-mail, employees number range, Key Decision Maker (CXOs) names, designation with e-mail & LinkedIn IDs,, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).

 

Section E : Individual Oncology Company Profile (with Active PreClinical Pipeline)

A to Z Alphabetical Profiles of Cancer Preclinical Drug Developer Companies (360 Companies)

Individual company Pages includes: Company Profile – Key technology platform, Oncology centered deals, collaborations and business insights, key investors and key partners.

Pre-Clinical Pipeline Profile – Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMEA Orphan drug status, company’s pre-clinical pipeline.

Management Profile –Address, Contact phone number, e-mail, employees number range, key manage­ment people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).

 

Section F : Individual Oncology Company Profile (with Active Discovery Pipeline)

A to Z Alphabetical Profiles of Cancer Discovery stage Companies (48 Companies)

Individual company Pages includes: Company Profile – Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

Discovery Pipeline Profile – Drug name, its targets, with details, of its development for various indications for cancer cure.

Management Profile –Address, Contact phone number, e-mail, employees number range, key manage­ment people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on May 2014).

Appendix A: Country Wise List of 931 Companies.

Appendix B: Complete 2237 Molecules List, along with their Developer’s Name.

Figure A.1 Qualitative Estimation of Oncology Drug Developers present in U.S.A vs. Europe vs. Asia vs. Australia vs. Canada vs. Rest of the World (931 Active Companies).

Figure A.2 Quantitative Estimation of clinical, preclinical & discovery companies present in U.S.A (468 companies

Figure A.3 Quantitative Estimation of clinical, preclinical & discovery companies present in Europe (270 companies)

Figure A.4 Quantitative Estimation of clinical, preclinical & discovery companies present in Asia (132 companies)

Figure A.5 Showing all individual 19 Countries in Europe and 8 Countries in Asia, along with the individual oncology focused companies present in these countries.

Figure A.6 Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Europe Region.

Figure A.7 Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Asia Region.

Figure A.8 Showing all individual 28 States in U.S.A, along with the individual number of oncology focused companies present in these States.

Figure A.9 Bar Graph for State-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in U.S.A

Figure A.10 Distribution of Active Cancer Drug Developers on the basis of year of Formation/Incorporation.

Figure A.11 Bar Graph showing incorporation pattern of cancer drug developers form 1991 onwards.

Figure A.12 Division of 931 cancer drug development companies on the basis of Human Resource employed.

 

Figure B.1 Distribution of Active Cancer Molecules in various Developmental Stages among Small, Biologics & others (2237 Molecules).

Figure B.2 Division of total cancer molecules in development among U.S.A, Europe, Asia & Rest of the World.

Figure B.3 Molecule Development Strategies:-

  1. Total molecules in development – Top 10 companies vs. remaining 921 companies.
  2. Top 10 companies – Small Molecules vs. Biologics.
  3. Remaining 921 companies – Small Molecules vs. Biologics.

Figure B.4 Clinical phase-wise (Ph I/PhII/PhIII), Preclinical & Discovery stage distribution of 2237 molecules.

Figure B.5 Phase-wise distribution of Small Molecules in various developmental stages for cancer treatment.

Figure B.6 Phase-wise distribution of Biologics in various developmental stages for cancer treatment.

Figure B.7 Clinical phase-wise division of cancer molecules in development in U.S.A, Europe, Asia & RoW.

Figure B.8 Protein Kinase in cancer drug development

  1. Total number of Targets in Development – Protein Kinases vs. others.
  2. Total number of Molecules – Protein Kinases vs. others.

C . Clinical phase-wise distribution of Protein Kinases in cancer drug development.

Figure B.9 Distribution of total Kinases in cancer clinical development in U.S.A, Europe, Asia & RoW.

Figure B.10 Top four Protein Kinases (Targets) in cancer clinical drug development (w.r.t molecules in development).

Figure B.11 Top three cancer Indications with highest numbers of Protein Kinases in clinical development.

Figure B.12 Protein Kinases Molecules development Strategies:-

  1. Total Kinases in development – Top 10 companies vs remaining 921 companies.
  2. Top 10 companies – clinical phase-wise distribution of Protein Kinases.
  3. Remaining 921 companies – clinical phase wise distribution of Protein Kinases.

 

Figure C.1 Distribution of Total Oncology Indications in various Development (4264 Active Cancer Drug Indications for 2231 Cancer Drugs under development)

  1. Relative Number of Cancer Drug Indications for Small Molecules vs Biologics vs Others.
  2. Comparative Clinical, Preclinical & Discovery Indications under development.

Figure C.2 Distribution of 4264 cancer drug development indications among USA, Europe, Asia and RoW.

Figure C.3 Cancer Clinical Indications Development Strategies:-

  1. Total indications in clinical trials – Top 10 companies vs remaining 513 companies.
  2. Top 10 companies clinical pipeline indications – Small Molecules vs Biologics.
  3. Remaining 513 companies clinical pipeline indications – Small Molecules vs Biologics vs NBCM.

Figure C.4 Global incidence of Lung Cancer.

Figure C.5 A. Lung Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.

  1. Companies with active drug development pipeline for Lung Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.6 Exploring Lung Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Lung cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Lung Cancer, between U.S.A vs. Europe vs. RoW.

Figure C.7 A. Phase-wise division of total Lung Cancer molecules in various developmental stages.

  1. Subtype division of Lung Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Lung Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.8 A. Distribution of Lung Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.9 Global incidence of Breast Cancer.

Figure C.10 A. Breast Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.

  1. Companies with active drug development pipeline for Breast Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.11 Exploring Breast Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Breast cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Breast Cancer, between USA vs. Europe vs. RoW.

Figure C.12 A. Phase-wise division of total Breast Cancer molecules in various developmental stages.

  1. Subtype division of Breast Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Breast Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.13  A. Distribution of Breast Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.14 Global incidence of Colorectal Cancer.

Figure C.15 A. Colorectal Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.

  1. Companies with active drug development pipeline for Colorectal Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.16 Exploring Colorectal Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Colorectal cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Colorectal Cancer among USA vs. Europe vs. RoW.

Figure C.17 A. Phase-wise division of total Colorectal Cancer molecules in various developmental stages.

  1. Subtype division of Colorectal Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Colorectal Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.18 A. Distribution of Colorectal Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Pre clinical/ Discovery development phases.

Figure C.19 Global incidence of Melanoma Cancer.

Figure C.20 A. Melanoma Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.

  1. Companies with active drug development pipeline for Melanoma Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.21 Exploring Melanoma Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Melanoma cancer clinical pipeline vs. remaining other

clinical companies pipeline molecules.

  1. Percentage of molecules in development for Lung Cancer, between USA vs. Europe vs. RoW.

Figure C.22 A. Phase-wise division of total Melanoma Cancer molecules in various developmental stages.

  1. Subtype division of Melanoma Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Melanoma Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.23 A. Distribution of Melanoma Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.24 Global incidence of Prostate Cancer.

Figure C.25 A. Prostate Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.

  1. Companies with active drug development pipeline for Prostate Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.26 Exploring Prostate Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Prostate cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Prostate Cancer, between USA vs. Europe vs. RoW.

Figure C.27 A. Phase-wise division of total Prostate Cancer molecules in various developmental stages.

  1. Subtype division of Prostate Cancer’s Phase II clinical molecules- Small, Biologics & Others.
  2. Subtype division of Prostate Cancer’s Phase I clinical molecules- Small, Biologics & Others.

Figure C.28 A. Distribution of Prostate Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.29 Global incidence of Ovarian Cancer.

Figure C.30 A. Ovarian Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.

  1. Companies with active drug development pipeline for Ovarian Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.31 Exploring Ovarian Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Ovarian cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Ovarian Cancer, between USA vs. Europe vs. RoW.

Figure C.32 A. Phase-wise division of total Ovarian Cancer molecules in various developmental stages.

  1. Subtype division of Ovarian Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Ovarian Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.33 A. Distribution of Ovarian Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.34 Global incidence of Pancreatic Cancer.

Figure C.35 A. Pancreatic Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.

  1. Companies with active drug development pipeline for Pancreatic Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.

Figure C.36 Exploring Pancreatic Cancer Development Strategies:-

  1. Comparison between Top 10 Companies, Pancreatic cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.
  2. Percentage of molecules in development for Pancreatic Cancer, between USA vs. Europe vs. RoW.

Figure C.37 A. Phase-wise division of total Pancreatic Cancer molecules in various development stages.

  1. Subtype division of Pancreatic Cancer’s Phase II clinical molecules- Small, Biologics & NBCM.
  2. Subtype division of Pancreatic Cancer’s Phase I clinical molecules- Small, Biologics & NBCM.

Figure C.38 A. Distribution of Pancreatic Cancer Pipeline in Small, Biologics & NBCM.

  1. Distribution of Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery development phases.

Figure C.39 Global incidence of Hepatocellular Carcinoma.

Figure C.40 Global incidence of Gastric Cancer.

Figure C.41 Global incidence of Multiple Myeloma.

Figure C.42 Global incidence of Leukemia.

Figure C.43 Global incidence of Non-Hodgkin Lymphoma.

Figure C.44 Global incidence of Hodgkin Lymphoma.

Figure C.45 Global incidence of Brain Cancer including Glioblastoma.

Figure C.46 Global incidence of Head & Neck Cancer.

Figure C.47 Global incidence of Renal Cell Carcinoma.

Figure C.48 Global incidence of Bladder Cancer.

Figure C.49 Global incidence of Thyroid Cancer.

Table A.1  Top 10 Cancer drug development companies (in terms of employee number).

Table B.1  Top 20 companies with highest number of cancer clinical molecules in development.

Table B.2  Monoclonal Antibodies in Clinical Trials (174 Molecules- their developer, partner, target, isotypes & indications).

Table B.3  Monoclonal Antibodies in Preclinical & Discovery stage (193 Molecules- their developer, target & indications).

Table B.4  Cancer Vaccines in Clinical development (134 Vaccines-their developer, partner, target, indications & comments).

Table B.5  Cancer Vaccines in Preclinical & Discovery development stage (50 Vaccines-their developer, target & indications).

Table B.6  Antibody Drug Conjugates in Clinical development (42 Molecules, developer, partner, target, indications & comments).

Table B.7  Radio-Immuno Conjugates in Clinical Development (10 Molecules, developer, partner, target, indications, comments).

Table B.8  Recombinant/Fusion Proteins based therapies in Clinical Development (49 Molecules, developer, partner, target, indications, comments).

Table B.9  Synthetic Peptides based therapies in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).

Table B.10  Gene Therapies & Oncolytic based therapies in Clinical Development (33 Molecules, developer, partner, target, indications, comments).

Table B.11 T cell based therapies in Clinical Trials (8 Molecules, developer, partner, target, indications, comments).

Table B.12  Stem cell based therapies in Clinical Trials (6 Molecules, developer, partner, target, indications, comments).

Table B.13 Other cell based therapies in Clinical Trials (5 Molecules, developer, partner, target, indications, comments).

Table B.14  Miscellaneous other Biologics in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).

Table B.15  Approved Kinase Inhibitors for Cancer Cure (Developer, type, target, approved since, 2013 sales, indications).

Table B.16 Expected New Kinases Launches in 2014-15 (Drug, developer, type, target, expected launch & indication).

Table B.17  Cancer Drug Targets – Protein Kinases (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s description).

Table B.18 Cancer Drug Targets – Tumor Necrosis Factor Family (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).

Table B.19  Cancer Drug Targets – G-coupled Protein Receptors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).

Table B.20 Cancer Drug Targets – Tumor Antigens (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).

Table B.21 Cancer Drug Targets – Transcription Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).

Table B.22 Cancer Drug Targets – Metabolic Enzymes (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target’s Description).

Table B.23 Cancer Drug Targets – Growth Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).

Table B.24 Cancer Drug Targets – Miscellaneous other Targets (individual target name, Gene, protein family, Drugs in development for the target, target Description).

 

Table C.1 Molecule Development Strategies – Top 10 companies Vs. Remaining 921 companies

(Comparison between total molecules, clinical phases, types, top 7 targets, top 9 indications and market capitalization).

Table C.2 Top selling chemotherapies for Lung Cancer.

Table C.3 Top selling targeted therapies for Lung Cancer.

Table C.4 Molecules in Ph III clinical trials for NSCLC (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.5 Monoclonal Antibodies in various drug development stages for the treatment of Lung Cancer.

Table C.6 Vaccines in various drug development stages for the treatment of Lung Cancer.

Table C.7 Miscellaneous other Biologics in various drug development stages for the treatment of Lung Cancer.

Table C.8 Non Small Lung Cancer (NSCLC) PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.9 Molecules in Ph III clinical trials for Lung Cancer (SCLC) (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.10 Small Cell Lung Cancer (SCLC) PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.11 Top selling Chemotherapies/Hormonal Therapies for Breast Cancer.

Table C.12 Top selling Targeted Therapies for Breast Cancer.

Table C.13 Molecules in Ph III clinical trials for Breast Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.14 Monoclonal Antibodies in various drug development stages for the treatment of Breast Cancer.

Table C.15 Vaccines in various drug development stages for the treatment of Breast Cancer.

Table C.16 Miscellaneous other Biologics in various drug development stages for the treatment of Breast Cancer.

Table C.17 Breast Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.18 Top selling chemotherapies for Colorectal Cancer.

Table C.19 Top selling targeted therapies for Colorectal Cancer.

Table C.20 Molecules in Ph III clinical trials for Colorectal Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.21 Monoclonal Antibodies in various drug development stages for the treatment of Colorectal Cancer.

Table C.22 Vaccines in various drug development stages for the treatment of Colorectal Cancer.

Table C.23 Miscellaneous other Biologics in drug development stages for the treatment of Colorectal Cancer.

Table C.24 Colorectal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.25 Top selling chemotherapies for Melanoma Cancer.

Table C.26 Top selling targeted therapies for Melanoma Cancer.

Table C.27 Molecules in Ph III clinical trials for Melanoma Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.28 Monoclonal Antibodies in various drug development stages for the treatment of Melanoma Cancer.

Table C.29 Vaccines in various drug development stages for the treatment of Melanoma Cancer.

Table C.30 Miscellaneous other Biologics in drug development stages for the treatment of Melanoma Cancer.

Table C.31 Melanoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.32 Other Skin Cancers Including Non-Melanoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.33 Top selling Chemotherapies for Prostate Cancer.

Table C.34 Top selling Targeted therapies for Prostate Cancer.

Table C.35 Molecules in Ph III clinical trials for Prostate Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.36 Monoclonal Antibodies in various drug development stages for the treatment of Prostate Cancer.

Table C.37 Vaccines in various drug development stages for the treatment of Prostate Cancer.

Table C.38 Miscellaneous other Biologics in drug development stages for the treatment of Prostate Cancer.

Table C.39 Prostate Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.40 Top selling chemotherapies for Ovarian Cancer.

Table C.41 Molecules in Ph III clinical trials for Ovarian Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.42 Monoclonal Antibodies in various drug development stages for the treatment of Ovarian Cancer.

Table C.43 Vaccines in various drug development stages for the treatment of Ovarian Cancer.

Table C.44 Miscellaneous other Biologics in drug development stages for the treatment of Ovarian Cancer.

Table C.45 Ovarian Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.46 Cervical Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.47 Fallopian Tube Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.48 Peritoneal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.49 Endometrial Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.50 Top selling chemotherapies for Pancreatic Cancer.

Table C.51 Top selling targeted therapies for Pancreatic Cancer.

Table C.52 Molecules in Ph III clinical trials for Pancreatic Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).

Table C.53 Monoclonal Antibodies in various drug development stages for the treatment of Pancreatic Cancer.

Table C.54 Vaccines in various drug development stages for the treatment of Pancreatic Cancer.

Table C.55 Miscellaneous other Biologics in drug development stages for the treatment of Pancreatic Cancer.

Table C.56 Pancreatic Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.57 Neuroendocrine Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.58 Esophageal Cancer Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.59 GastroIntestinal Stromal Tumor Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.60 Biliary Tract Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.61 Gall Bladder Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.62 Midgut Carcinoid Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.63 Cholangiocarcinoma Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.64 Anal Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.65 Top selling targeted therapies for Hepatocellular Carcinoma.

Table C.66 Molecules in Ph III clinical trials for Hepatocellular Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.67 Hepatocellular Carcinoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.68 Top selling targeted therapies for Gastric Cancer.

Table C.69 Molecules in Ph III clinical trials for Gastric Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.70 Gastric Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.71 Molecules in Ph III clinical trials for Multiple Myeloma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.72 Multiple Myeloma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.73 Top selling targeted therapies for Leukemia.

Table C.74 Molecules in Ph III clinical trials for Leukemia (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.75 Acute Myeloid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.76 Acute Myelogenous Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.77 Acute Lymphoid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.78 Acute Lymphocytic Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.79 Chronic Myeloid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.80 Chronic Myelogenous Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.81 Chronic Myelomonocytic Leukemia PipelineClinical stage drugs, developers, partners & targets.

Table C.82 Chronic Lymphoid Leukemia PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.83 Top selling targeted therapies for Non Hodgkin Lymphoma.

Table C.84 Molecules in Ph III clinical trials for Non Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.85 Non Hodgkin Lymphoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.86 Waldenstrom’s MacroglobulinemiaClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.87 Molecules in Ph III clinical trials for Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.88 Hodgkin Lymphoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.89 Molecules in Ph III clinical trials for Brain Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.90 Glioblastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.91 Neuroblastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.92 Medullolastoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.93 Anaplastic Astrocytoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.94 Top selling targeted therapies for Head & Neck Cancer.

Table C.95 Molecules in Ph III clinical trials for Head & Neck Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.96 Head & Neck Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.97 Nasopharynx Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.98 Oral Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.99 Top selling targeted therapies for Renal Cell Carcinoma.

Table C.100 Molecules in Ph III clinical trials for Renal Cell Carcinoma (Drug, developer, partner, indications,  combination drugs in trial, line of therapy, target, expected launch).

Table C.101 Renal Cell Carcinoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.102 Wilm’s Tumor PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.103 Top selling targeted therapies for Bladder Cancer.

Table C.104 Molecules in Ph III clinical trials for Bladder Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.105 Bladder Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.106 Top selling targeted therapies for Thyroid Cancer.

Table C.107 Molecules in Ph III clinical trials for Thyroid Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.108 Thyroid Cancer PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.109 Molecules in Ph III clinical trials for Sarcoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).

Table C.110 Sarcoma PipelineClinical, Preclinical & Discovery stage drugs, developers, partners & targets).

Table C.111 Other Rare Cancer Indications Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.

Table C.112 Orphan Drug Status cancer molecules in clinical development (145 Molecules with 174 orphan indications)

(Drug Name, Phase, Orphan indication, developer, USFDA/EMEA approvals).

Table C.113 US FDA New Oncology Drug Approvals -2013 (Developer, month of approval, partner, drug proprietary name, established name, approved indications with disease state)

Table C.114 Oncology Clinical Pipeline- Major Drug Failures 2013 (Drug, Developer, month, phase, indications, comments).

Box C.1 Lung Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.2 Strong Clinical Pipeline Companies – Lung Cancer.

Box C.3 Breast Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.4 Strong Clinical Pipeline Companies – Breast Cancer.

Box C.5 Colorectal Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.6 Strong Clinical Pipeline Companies – Colorectal Cancer.

Box C.7 Melanoma Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.8 Strong Clinical Pipeline Companies – Melanoma Cancer.

Box C.9 Prostate Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.10 Strong Clinical Pipeline Companies – Prostate Cancer.

Box C.11 Ovarian Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.12 Strong Clinical Pipeline Companies – Ovarian Cancer.

Box C.13 Other Gynecologic Malignancies Indications.

Box C.14 Pancreatic Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.15 Strong Clinical Pipeline Companies – Pancreatic Cancer.

Box C.16 Other Gastrointestinal Indications.

Box C.17 Hepatocellular Carcinoma-An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.18 Gastric Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.19 Multiple Myeloma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.20 Leukemia- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.21 NonHodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.22 Hodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.23 Brain Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.24 Head & Neck Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.25 Renal Cell Carcinoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.26 Bladder Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.27 Thyroid Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Box C.28 Sarcoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.

Other Reports in this series

For Purchase, Kindly check the latest report available in this series...

Oncology Intelligence 2013
Comprehensive Decision Making Intelligence derived from Active 624 Oncology Drug Developers.
Oncology Intelligence 2014
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
Oncology Intelligence 2017
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
Oncology Intelligence 2020
Upcoming Comprehensive Decision Making Report derived from Active 1250+ Oncology Drug Developers.
January 2013
March 2014
January 2017
Feburary 2020